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Abstract
Background: To investigate the presence of peripheral artery disease (PAD) via the ankle brachial index (ABI) in
patients with known cardiovascular and/or cerebrovascular diseases or with at least one risk factor for
atherothrombosis.
Methods: Patients with a history of atherothrombotic events, or aged 50-69 years with at least one cardiovascular
risk factor, or > = 70 years of age were included in this multicenter, cross-sectional, non-interventional study
(DIREGL04074). Demographics, medical history, physical examination findings, and physician awareness of PAD
were analyzed. The number of patients with low ABI (< = 0.90) was analyzed.
Results: A total of 530 patients (mean age, 63.4 ± 8.7 years; 50.2% female) were enrolled. Hypertension and
dyslipidemia were present in 88.7% and 65.5% of patients, respectively. PAD-related symptoms were evident in
about one-third of the patients, and at least one of the pedal pulses was negative in 6.5% of patients. The
frequency of low ABI was 20.0% in the whole study population and 30% for patients older than 70 years. Older
age, greater number of total risk factors, and presence of PAD-related physical findings were associated with
increased likelihood of low ABI (p < 0.001). There was no gender difference in the prevalence of low ABI, PAD
symptoms, or total number of risk factors. Exercise (33.6%) was the most common non-pharmacological option
recommended by physicians, and acetylsalicylic acid (ASA) (45.4%) was the most frequently prescribed medication
for PAD.
Conclusion: Our results indicate that advanced age, greater number of total risk factors and presence of PAD-
related physical findings were associated with increased likelihood of low ABI. These findings are similar to those
reported in similar studies of different populations, and document a fairly high prevalence of PAD in a
Mediterranean country.
* Correspondence: akbozkurt@yahoo.com
† Contributed equally
1Department of Cardiovascular Surgery, Istanbul University Cerrahpasa
Medical School, Istanbul, Turkey
Full list of author information is available at the end of the article
Bozkurt et al. BMC Cardiovascular Disorders 2011, 11:4
http://www.biomedcentral.com/1471-2261/11/4
© 2011 Bozkurt et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Previous studies have consistently documented that per-
ipheral artery disease (PAD) is a significant predictor of
future cardiovascular events, such as myocardial infarc-
tion or stroke [1-3]. Epidemiological studies have esti-
mated that the prevalence of PAD in the general
population is up to 10%, and is twice as high in people
older than 70 years [4,5]. Moreover, for each patient with
symptomatic PAD, there are approximately three to four
undiagnosed subjects with asymptomatic PAD [6].
Both symptomatic and asymptomatic PAD have
been found to be associated with increased risk of cardio-
vascular disease (CVD) and adverse risk profiles [5,7,8].
The Reduction of Atherothrombosis for Continued
Health (REACH) registry indicated that 60% of patients
with PAD had atherosclerotic disease in other vascular
beds [9]. PAD patients were reported to have a 6.6-fold
greater risk of death from coronary heart disease (CHD)
than patients without PAD, and a 3.1-fold greater mortal-
ity from any cause [10,11]. Cross-sectional studies showed
that almost half of all PAD subjects seemed to have some
clinical evidence of CHD or cerebrovascular disease [12].
However, due to the silent nature of this disease and the
subtle findings on physical examination [11,13], PAD has
been considered the least effectively managed major ather-
osclerotic vascular disorder [5,9]. Although PAD is a
strong prognostic marker for future cardiovascular events,
previous research indicates that only a small fraction of
patients with PAD are properly diagnosed [14].
The ankle brachial index (ABI) is a sensitive and cost-
effective screening tool for PAD. In addition to its value in
the diagnosis of PAD, the ABI can also be used to assess
generalized atherosclerosis [15]. Previous studies have
shown that a low ABI (≤ 0.90) has a specificity of greater
than 98% for the diagnosis of PAD and a specificity of 92%
for the prediction of CHD and stroke [16-18]. Among the
elderly, an ABI of 0.90 or less indicates subclinical athero-
sclerosis and is a strong predictor of total mortality and
cardiovascular morbidity and death in those with no prior
history of clinical cardiovascular disease [19].
The primary aim of the present study was to investigate
the use of low ABI (≤ 0.90) as an indicator of PAD in a
target population admitted to internal medicine outpati-
ent clinics in Turkey. Our secondary objectives were to
evaluate the characteristics of individuals with low ABIs
with respect to gender and the presence of established
CVD and/or major cardiovascular risk factors, and to
assess physician awareness of PAD management.
Methods
Study population and objectives
The CAREFUL study enrolled patients admitted to
internal medicine outpatient clinics in Turkey from
February 23 to June 19, 2009. In this national, multi-
center, cross-sectional, ando b s e r v a t i o n a ls t u d y( D I R -
EGL04074), individuals from 27 centers, representative
of the geographical composition of the whole country,
were examined. To assure that our study population
was representative of Turkey as a whole, participating
centers were selected by the Project Advisory Board
using stratified selection based on geography and type of
institution among all internal medicine clinics in Tur-
key, and on the distribution of investigators in relation
to type of institutions where they worked (university
hospital, state hospital, or private hospital).
Inclusion and exclusion criteria
The main inclusion criteria were age of 50-69 years and
presence of established CVD or at least one major cardi-
ovascular risk factor (smoking, diabetes, hypertension,
and dyslipidemia, as defined by the TASC II report
[20]). The exclusion criteria were presence of previously
diagnosed PAD, refusal to participate, and conditions
that required hospitalization, such as cancer or a life
threatening illness.
Working protocol
T h eC A R E F U Ls t u d yw a sa p p r oved by the local ethics
committee prior to initiation, and all participants pro-
vided written informed consent following a detailed
explanation of the objectives and protocol. During the
study period of 4 months, in each center, the first patient
of each investigator’s working day who fulfilled the inclu-
sion criteria was invited to participate; if this patient
refused, then the next patient was asked. This continued
until there were 20 patients recruited from each center.
Each patient was examined at a single visit, and there
were no interventions involving ongoing medications
and/or decisions of the physicians. Patient demographics,
history of atherothrombotic events, smoking status, pre-
sence of hypertension, diabetes mellitus (DM), dyslipide-
mia (risk factors for PAD), and medications in the last 6
months (including antihypertensives, anti-diabetics, lipid-
lowering drugs, and antithrombotic agents) were
recorded during this visit. Blood pressure, heart rate,
body weight, height, body mass index (BMI), waist cir-
cumference, and physical examination findings specific to
PAD (absence of pedal pulses, arterial murmur, and
trophic changes of the foot) were also recorded.
For patients diagnosed with PAD, the recommended
treatment strategy was also noted. A three-item modi-
fied Edinburgh Claudication Questionnaire on PAD
symptoms was given to all patients and an eight-item
questionnaire on awareness of PAD was given to the
physicians [21]. The PAD awareness questionnaire
included questions about the age group of patients who
should be considered for measurement of ABI, evalua-
tion of obese/diabetic/actively smoking patients by
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PAD, the objectives of PAD treatment (according to
Turkish Society of Cardiovascular Surgery), the role
of medical history and physical examination in the diag-
nosis of PAD, the diagnostic option(s) for patients who
required further investigation, and the “treatment of
choice” for ischemic events.
Measurement of ankle brachial index
Measurement of systolic pressures of the four limbs was
performed in all patients using a standard sphygmoman-
ometer in a quiet room, with the patient supine for at
least 5 min before measurement. Right and left arm and
ankle (posterior tibial artery and dorsalis pedis artery)
systolic blood pressures were measured by trained physi-
cians using a handheld Doppler ultrasound (Vascular
Doppler 8 MHz, Hedeco, Japan) and a manually operated
blood pressure cuff with a 15 cm-wide bladder. A cycle
of measurements (right arm, right ankle, left ankle, left
arm) was repeated, and the means of two measurements
for each limb were used to calculate the ABI. Finally, the
ratio of the highest systolic pressure in the ankle to the
higher of the left or right brachial systolic pressure was
used to define the ABI [15,22]. An ABI of 0.90 or less
was considered abnormal and indicative of PAD [11].
Statistical analyses
The AGATHA study reported that 30.9% of patients
with cardiovascular risk factors had ABIs of 0.90 or less
and that 27.6% of these patients had involvement in
both arterial beds [23]. Thus, based on the estimation of
the rate of an event (ABI ≤ 0.90) of 30%, an error of 6%,
a 95% confidence interval (CI), a of 0.05, and power of
80%, the sample size was calculated as 437. Assuming a
missing data probability of 10-15%, we enrolled ~500
patients. Statistical analysis was performed with SPSS
version 13.0 (SPSS Inc. Chicago, IL, USA). Chi-square
(c
2)a n dF i s c h e r ’s exact tests were used for comparisons
of categorical data. Data are expressed as means ± stan-
dard deviations (SDs) or as percent (%) and 95% CI
where appropriate. A p-value less than 0.05 was consid-
ered statistically significant.
Results
Demographics of the study population
A total of 533 patients underwent ABI measurement for
this study. Due to inappropriate enrollment, three parti-
cipants from different centers were excluded prior to
analysis. Among the 530 enrolled patients, 264 were
male (49.8%) and 266 were female. Mean age was 63.4 ±
8.7 years in the entire group, and was 63.2 ± 8.5 years
(range: 50-84) for men and 63.8 ± 8.9 years (range
50-88) for women. Among men, 39% were 50-59 years
of age, 37.9% were 60-69, 20.1% were 70-79, and 3%
were 80-89 years. Among women, 37.2% were 50-59
years of age, 39.5% were 60-69, 16.2% were 70-79, and
7.1% were 80-89 years. Gender distributions of the dif-
ferent age groups were similar.
Presence of cardiovascular disease or risk factors and
concomitant drug use
A total of 27.9% of patients had histories of CHD and
7.4% had histories of cerebrovascular disease. CHD was
more prevalent in men than in women (33.3% for men
vs. 22.6% for women, p = 0.006), but history of cerebro-
vascular disease was similar in both genders (7.6% for
men vs. 7.1% for women, p = 0.848). Regarding risk fac-
tors, 42.8% of participants identified themselves as active
or past smokers, 88.7% were hypertensive or were trea-
ted for this condition, 65.5% had dyslipidemia or were
treated for this condition, and 59.4% had type II diabetes
mellitus (DM) or were treated for this condition.
Table 1 provides the gender distribution, clinical back-
ground, and vital signs for all enrolled patients. Females
were more likely to have DM and be nonsmokers than
males (p <0 . 0 1a n dp < 0.001, respectively; Table 1).
There were no gender differences in blood pressure,
heart rate, BMI, or waist circumference (Table 1).
Among all 530 enrolled patients, 58 (10.9%) had one,
186 (35.1%) had two, 215 (40.6%) had three, and 71
(13.4%) had four major cardiovascular risk factors.
There was no gender difference in the number of
accompanying risk factors.
A total of 942 antihypertensive drugs were used in the
entire study population. The most frequently prescribed
antihypertensives were renin-angiotensin system block-
ers (angiotensin converting enzyme inhibitors [ACEI]
and angiotensin receptor blockers [ARB]) (n = 399,
42.4%), followed by diuretics (n = 254, 27%), calcium
channel blockers (n = 153, 16.3%), beta-blockers
(n = 114, 12%), and alpha-blockers (n = 22, 2.3%). The
mostly commonly used antidiabetic drug was metformin
(38.8%), the most common lipid lowering drug was ator-
vastatin (69.5%), and the most common antithrombotic
drug was acetyl salicylic acid (ASA) (83.3%).
PAD symptoms and findings, and ankle brachial index
measurements
The three-item questionnaire on PAD symptoms indi-
cated that 42.9% of patients had pain or discomfort
while walking and that 25.1% had pain or discomfort
while sitting. A total of 35.3% reported relief from pain
following 10 min of rest. Physical examinations indi-
cated absence of pedal pulse in 6.5% of patients, arterial
murmur in 6.6% of patients, and trophic foot changes in
17.6% of patients.
An abnormal ABI (≤ 0.90) was present in 20.0% of the
participants, with no difference between males and
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quency of low ABI (≤0.90) was higher for older patients,
and almost exceeded 30% for patients more than 70 years
old. Advanced age, higher number of risk factors, arterial
murmur, trophic changes in the foot, and PAD symp-
toms were associated with increased likelihood of low
ABI (p < 0.001; Table 2). The prevalence of low ABI was
35.8% (n = 62) in the 173 patients with histories of cardi-
ovascular events and was 19.1% in patients with intact
low extremity pulses. Among patients who had an absent
ankle pulse, 67.6% had an ABI greater than 0.90. A total
of 58.2% (53 of 91) of patients with trophic foot changes
had ABIs greater than 0.90. A total of 15.1% of patients
with low ABI had no trophic foot changes.
Table 2 shows the frequency of low ABI based on the
number of major cardiovascular risk factors. For the
entire study population, 53.9% (n = 286) had three or
more major cardiovascular risk factors (as defined in
our according inclusion criteria) and 25.1% of these
patients (n = 72) had ABIs indicative of PAD. Among
patients with low ABIs, 67.9% had three or more risk
factors. There was a significant association of low ABI
and number of risk factors in men (p =0 . 0 2 )b u tn o ti n
women (p = 0.134). Women with low ABIs were more
likely to have fewer risk factors (Table 2).
We separately evaluated patients with DM (n = 315)
and those without DM (n = 215). In the DM group, the
frequency of low ABI was 22.9% (21.7% in women
vs. 24.3% in men, p = 0.589); in the non-DM group, the
frequency of low ABI was 15.8% (13.2% in women vs.
17.7% in men, p = 0.474).
We also calculated the percentage of patients with
abnormally high ABIs (> 1.4). There were 32 partici-
pants (6%) who had ABIs greater than 1.4, and high ABI
was more common in men (n = 23, 8.7%) than in
women (n = 9, 3.4%) (p < 0.001). When a lower cut-off
value was used (>1.30), 64 participants (12%) had high
ABIs, and high ABI was also more common in men (n =
46, 17.4%) than in women (n = 18, 6.7%) (p < 0.001).
Diagnostic and therapeutic recommendations by the
physicians
A total of 210 participants (114 patients with ABI ≤
0.90, 96 patients with ABI >0.90) were recommended
Table 1 Gender-based distribution clinical background
and vital signs of the study population
Male
(n = 264)
Female
(n = 266)
Past history of coronary heart disease n(%)
Overall 88(33.3)* 60(22.6)
Stable angina pectoris 22(25.0) 23(38.3)
Unstable angina pectoris 7(8.0) 4(6.7)
Coronary bypass surgery 30(34.1) 13(21.7)
Percutaneous coronary intervention 25(28.4) 13(21.7)
Myocardial infarction 10(11.4) 13(21.7)
Past history of cerebrovascular disease
Overall 20(7.6) 19(7.1)
Transient ischemic attack 11(55.0) 14(73.7)
Ischemic stroke 7(35.0) 5(26.3)
Carotid angioplasty 2(10.0) 0(0.0)
Carotid endarterectomy 0(0.0) 0(0.0)
Risk factor profile
Smoking status
None 79(29.9)** 224(84.2)
Former 130(49.2) 18(6.8)
Active 55(20.8) 24(9.0)
Type II DM 140(53.0)* 175(65.8)
Hypertension 237(89.8) 233(87.6)
Dyslipidemia 165(62.5) 182(68.4)
Vital signs mean ± SD
Systolic blood pressure (mm/Hg) 141.4 ± 21.5 146.7 ± 21.5
Diastolic blood pressure (mm/Hg) 85.4 ± 12.1 87.4 ± 11.6
Pulse (beat/min) 80.5 ± 9.5 81.5 ± 10.0
Weight (kg) 81.8 ± 12.7 78.3 ± 14.7
Height (cm) 169.9 ± 6.6 158.3 ± 7.0
Waist circumference (cm) 101.5 ± 10.8 102.6 ± 11.8
* p < 0.01 and ** p < 0.001; compared to female patients.
Table 2 Ankle Brachial Pressure Index (ABI) in terms of
demographics, clinical features and risk factors
ABI ≤0.90
(n = 106)
ABI >0.90
(n = 424)
Gender n(%)
Males 56(52.8)
a 208(49.1)
Females 50(47.2)
b 216(50.9)
Age groups
50-59 years 20(18.9)
+ 182(42.9)
60-69 years 49(46.2) 156(36.8)
70-79 years 37(34.9)
+ 86(20.3)
Presence of risk factors
Only 1 risk factor 5(4.7)
q 53(12.5)
2 risk factors 29(27.4) 157(37.0)
3 risk factor 53(50.0)
q 162(38.2)
4 risk factor 19(17.9) 52(12.3)
Past history of atherothrombotic event 62(58.5)
c 111(26.2)
PAD symptoms
Pain/discomfort while walking 75(70.8)** 155(36.6)
Pain/discomfort while standing or sitting 15(14.2)* 116(27.4)
Pain/discomfort relieve in <10 minutes 31(29.2) 117(27.5)
Positive findings on physical examination
Pedal pulse 94(88.8) 397(93.4)
Arterial murmur 17(16.0)** 16(3.8)
Trophic changes of the foot 38(35.8)** 53(12.5)
95% CI :
a16.28 - 26.14;
b14.10 - 23.49 and
c28.69 - 42.98;
+p < 0.001 and
qp < 0.05.
** p < 0.001 and *p < 0.01; compared to absence of the specific finding.
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diagnostic procedures wasm o r ec o m m o ni np a t i e n t s
with abnormal ABI (0.05 >p > 0.001; Table 3). Overall,
ultrasonography was the most frequently used procedure
(61.4%), regardless of ABI (Table 3).
Exercise (p < 0.001), revascularization (p < 0.001),
and endovascular interventions (p < 0.05) were more
commonly recommended for patients with low ABI
(Table 3).
Pharmacotherapy was recommended to 317 of 530
patients, and ASA was the most frequently prescribed
medication (45.4%), followed by pentoxyphylline (16.4%)
and clopidogrel (16.09%). The other prescribed medica-
tions were statins, warfarin, diosmine, diosmine plus
hesperidine, metformin, nifedipine, dipyridamole, and
calcium dobesilate.
Personal awareness and PAD management by the
CAREFUL investigators
We evaluated physician awareness of PAD and its man-
agement by an eight-item questionnaire before initiation
of the study (Table 4). The results indicated that physi-
cians in internal medicine clinics were more likely to
order an ABI measurement for males and for patients
with younger ages (note that the minimum age is 55 years
in the questionnaire). While they ordered an ABI mea-
surement in about two-thirds of patients with DM and
smoking habits, they ordered the test for less than half of
obese individuals. Almost 80% of physicians thought that
patient history and physical examination findings showed
no evidence of PAD, and 95% were aware of the diagnostic
success of ABI measurement and Doppler examination.
The recommended medication for management of PAD
varied, but the majority agreed on the benefits provided by
smoking cessation and exercise.
Discussion
In our study population, the overall frequency of low
ABI (≤ 0.90) was 20.0%, and the frequency of low ABI
was similar for males and females. Older age, greater
number of risk factors, and presence of PAD-related
physical findings were associated with increased likeli-
hood of low ABI.
Previous studies have shown that a low ABI has speci-
ficity greater than 98% for the diagnosis of PAD and
specificity greater than 92% for the prediction of CHD
and stroke [16-18]. The frequency of PAD, as deter-
mined by low ABI in adults with no known CVD, varies
from 3.7 to 14% in different populations [4,8,15,24-29].
However, for people with established CVD or other
measures of atherosclerosis, the prevalence of low ABI
was reported as 15% to 40% [6,7,23,30], in accordance
with the results of the CAREFUL study. Another signifi-
cant finding in the present study is that age above 70
years is associated with a 30% prevalence of PAD, inde-
pendent of the presence of a major risk factor for CVD.
This is also in accordance with a previous study with a
similar design of a different population [6].
Previous studies have reported different results regard-
ing gender differences in the prevalence of low ABI. In
our study, the frequency of low ABI was similar in
women and men with established CVD (other than
PAD) or cardiovascular risk factors. These results are in
line with previous studies with similar designs, although
subgroup analysis indicatedt h a td i s e a s ew a sm o r ep r e -
valent in men with established CVD [31,32]. The Ather-
osclerosis Risk in Communities Study (ARIC) cohort
study indicated that low ABI was rare in middle-aged
and younger people [33]. Likewise, other studies indi-
cated that the prevalence of low ABI increases substan-
tially with age [1,15]. Thus, our results, which indicate
an increased prevalence of low ABI in older patients, are
compatible with these previous studies.
DM is accepted as a CVD equivalent, but the preva-
lence of PAD in DM patients ranges from 10% [34] to
20.9% [35], comparable to the ratio reported in refer-
ence populations. We found a higher prevalence of PAD
in patients with DM relative to previous reports and
relative to the average of the general study group. The
presence of DM increases the risk of PAD more than
f o u r - f o l d[ 3 6 ] ,a n dt h eA m e r ican Diabetes Association
recommends PAD screening by ABI every five years for
individuals with DM, even before the age of 50 years or
in the presence multiple risk factors [37].
The prevalence of high ABI was 6% for a cut-off of
1.40 and 12% for a cut-off of 1.30, indicating a similar
or a somewhat higher incidence than several previous
studies [8,38,39]. Although the mechanism is not clear,
there is an established association between elevated ABI
Table 3 Evaluation of Ankle Brachial Pressure Index (ABI)
in terms of diagnostic methods and selected treatments
ABI ≤ 0.90
(n = 106)
ABI >0.90
(n = 424)
Suggested diagnostic method n(%)
Conventional angiography 17(14.9)** 15(15.6)
Computed-tomography angiography 4(3.5)* 3(3.1)
Magnetic resonance angiography 23(20.2)** 10(10.4)
Ultrasonography 70(61.4)** 68(70.8)
Recommended treatment
Exercise 83(78.3)** 95(22.4)
Revascularization 31(29.2) ** 4(0.9)
Endovascular interventions 4(3.8)* 2(0.5)
Surgery 2(1.9) 1(0.2)
*p < 0.05 and **p < 0.001; compared to ratio of treatment suggestion for
patients having ABI >0.90.
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that elevated ABI may indicate the presence of general-
ized arterial stiffness [40], which places an individual at
high or very high risk, even in the absence of other risk
factors [41].
A previous longitudinal study, which showed that
symptomatic and asymptomatic subjects with PAD had
higher cardiovascular mortality than subjects without
PAD, indicates the prognostic importance of asympto-
matic PAD [10]. Previous studies reported a prevalence
of PAD-related symptoms (mainly intermittent claudica-
tion) from 5.3% to 18.9% [7]. This low prevalence was
interpreted as being due to elderly people not walking
enough to experience symptoms because of impaired
vascularization of the extremities or other disorders,
such as osteoarthritis. In contrast, the prevalence of
PAD symptoms was 35% in our population of patients,
who were all more than 50 years old. However, although
a previous study reported that women with PAD were
less likely than men to report symptoms of intermittent
claudication [7], we found no such difference in the pre-
sent study. In fact, such differences in demographic dis-
tributions of screened populations or analysis of
populations with higher risk for PAD were indicated to
be the causes of the differences in the prevalence esti-
mates of published studies [42,43].
Signs and symptoms may be inadequate for the diag-
nosis of PAD, so previous researchers have proposed
the use of non-invasive testing when history and vascu-
lar examination yield ambiguous results [31]. In this
context, a previous study illustrated the difficulty in
using clinical symptoms to diagnose PAD, because 47%
Table 4 Answers to PAD questionnaire applied to investigators expressed as n(%) (n = 53)
In which age group (years) of your patients do you consider to measure ABI in your clinic?
55-59 60-64 65-69 70-74 75-79 ≥80
For male patients 40 (75.5) 29 (54.7) 31 (58.5) 21 (39.6) 20 (37.7) 17 (32.1)
For female patients 31 (58.5) 31 (58.5) 32 (60.4) 21 (39.6) 20 (37.7) 17 (32.1)
Do you evaluate obese patients by physical examination and ABI with the suspect of PAD?
Yes 24(45.3)
Do you evaluate diabetic patients by physical examination and ABI with the suspect of PAD
Yes 35(66.0)
Do you evaluate smokers by physical examination and ABI with the suspect of PAD?
Yes 33(62.5)
What are the objectives of PAD treatment according to Turkish Society of Cardiovascular Surgery?
To control symptoms 39(73.6)
To prevent amputation 45(84.9)
To increase survival 46(86.8)
Do “patient history” and “physical examination” show that your patient has PAD?
Yes 12(22.6)
What should be the option(s) of your patient for the further investigation of PAD?
ABI + Doppler 50(94.3)
Cardiovascular surgery consultation 16(30.2)
Nothing, routine follow up 3(5.7)
What are the treatments of choice for ischemic events?
Continue Add Stop Contraindicate
ASA 48(92.5) 16(30.2) 0(0.0) 0(0.0)
Clopidogrel 30(56.6) 28(52.8) 0(0.0) 0(0.0)
Cilostazole 9(17) 12(22.6) 0(0.0) 0(0.0)
Statins 41(77.4) 24(45.3) 0(0.0) 0(0.0)
Other lipid lowering drugs 26(49.1) 22(41.5) 1(1.9) 0(0.0)
ACE inhibitors 38(71.7) 21(39.6 0(0.0) 0(0.0)
Other antihypertensives 24(45.3) 24(45.3) 3(5.7) 1(1.9)
Warfarin 23(43.4) 21(39.6) 3(5.7) 0(0.0)
Antihyperglycemic drug 40(75.5) 17(32.1) 0(0.0) 0(0.0)
Stop smoking program 45(85.9) 20(37.7) 1(1.9) 1(1.9)
Walking-exercise prog. 43(81.1) 23(43.4) 1(1.9) 0(0.0)
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[11]. Accordingly, symptoms suggested a diagnosis of
PAD in 35% of our population, and positive findings
indicating PAD were evident in the physical examination
in only 6-17% of our patients, whereas abnormal ABIs
confirmed PAD diagnosis in 20% of our population. In
fact, ABI is considered most beneficial in identifying
asymptomatic individuals, rather than those with preex-
isting clinical disease, who are already targeted for inter-
vention [15]. Furthermore, we found that the likelihood
of having low ABI was higher in the presence of PAD-
related symptoms. In support of this finding, a previous
study found that most atherosclerotic events occurred in
symptomatic patients with low ABIs [26].
The CAREFUL study indicated that arterial murmur
or trophic changes were associated with the presence of
low ABI. However, the prevalence of low ABI in partici-
pants with intact low extremity pulses on physical
examination was 19.1%, similar to the percentage in the
whole study population. It is known that the absence of
low extremity pulse is indicative of PAD, but the pre-
sence of low extremity pulses is not sufficient to rule
out PAD [20]. In our study, patients without low extre-
mity pulses had almost a two-fold higher prevalence of
PAD. Thus, the absence of lower extremity pulse is
insufficient for a firm diagnosis of PAD.
An additional goal of the present study was to assess
physician awareness of PAD. In particular, we consid-
ered physicians’ identification of patient risk, symptoms
and clinical findings, diagnostic procedures, and patient
management. We noted that diagnostic and follow-up
procedures selected by the CAREFUL investigators were
comparable to management recommendations in the
guidelines [20]. Physicians who participated in our study
indicated that they evaluated subjects with DM, smo-
kers, and obese individuals by physical examination and
ABI based on the suspicion of PAD. Based on Turkish
Society of Cardiovascular Surgery guidelines, the main
objectives of PAD treatment are to increase patient sur-
vival, prevent amputation, and control symptoms. On
the other hand, almost half of physicians studied here
reported that they had no clear idea of the role of
patient history and physical examination in the diagnosis
of PAD. This may not be surprising, because clinical
examination alone does not allow confirmation or exclu-
sion of PAD and cannot be used for definitive clinical
decision-making [44].
In line with the latest guidelines [20,45], pharma-
cotherapy was recommended for more than half of our
study population. Likewise, the majority of our physi-
cians recommended ASA. Although the overall rate of
pharmacotherapy administration in our study (59.8%)
was better than that reported in the REACH registry
(28.7%), use of antiplatelet therapy in our patients
(45.43%) was much lower than in the REACH registry
(81.7%) [9]. Furthermore, although not reflected in real
clinical practice, half of our investigators identified that
addition of clopidogrel to their treatments could be a
therapeutic option for ischemic events. For this reason,
as indicated in the literature [46], it seems necessary to
improve adherence to PAD treatment guidelines, as evi-
dence suggests this would improve patient outcome.
Our physicians had excellent awareness of the benefits
of exercise, particularly for people with low ABIs, and
this was recommended by over 80% of physicians. On
the other hand, despite the strong evidence concerning
available recommendations, recent data from the
REACH registry indicate a significant gap between treat-
ment recommendations for PAD and actual clinical
practice [9].
T h em a i nl i m i t a t i o n so ft h ep r e s e n ts t u d yw e r et h e
questionable representativeness of our study population
(ecological fallacy), the cross-sectional study design, and
the lack of blood sample analysis. Nevertheless, our
findings suggest that measurement of ABI has the
potential to improve estimation of cardiovascular risk
because it is a simple, inexpensive, and rapid measure-
ment tool, and can detect the presence of peripheral
atherothrombosis in patients with current or prior his-
tory of other vascular disease and, more importantly, in
at-risk patients.
Conclusions
In conclusion, we found a significantly higher prevalence
of low ABI in older individuals, those with more total
risk factors, and those with PAD symptoms. The present
study emphasizes the diagnostic and prognostic implica-
tions of low ABI in high-risk subjects, and the results
are comparable to similar registries of different
populations.
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